| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
MB-3 primarily targets the histone acetyltransferase (HAT) domain of MOZ (KAT6A) and KAT6B. By inhibiting these enzymes, it reduces the acetylation of histone H3 at lysine residues (H3K9, H3K14), which are important for transcriptional activation. This leads to changes in gene expression, including the downregulation of genes involved in cell proliferation and survival. The compound has shown selectivity for MOZ/KAT6A over other HATs.
|
|---|---|
| ln Vitro |
In vitro, MB-3 inhibits MOZ HAT activity in cell-free assays with IC50 values in the low micromolar range. It reduces histone H3 acetylation in cancer cell lines, leading to growth inhibition and induction of differentiation. MB-3 has been shown to inhibit the proliferation of AML cell lines and primary AML cells, with IC50 values typically ranging from 5-50 μM depending on the cell line. The compound also induces apoptosis in some cancer cell lines.
|
| ln Vivo |
In vivo, MB-3 has been studied in mouse models of AML and other cancers. It has shown efficacy in reducing tumor growth and extending survival in xenograft models. The compound's effects are attributed to its inhibition of MOZ/KAT6A HAT activity and the resulting changes in gene expression. Specific dosing regimens and efficacy outcomes are detailed in the scientific literature.
|
| Enzyme Assay |
The in vitro activity of MB-3 is assessed using cell-free HAT activity assays. Recombinant MOZ or KAT6A is incubated with histone H3 or a peptide substrate and acetyl-CoA in the presence of varying concentrations of MB-3. The incorporation of acetyl groups into the substrate is measured using radioactive or fluorescence-based detection methods. The IC50 is determined from dose-response curves. For cellular assays, cells are treated with MB-3, and histone acetylation is assessed by Western blotting using acetylation-specific antibodies.
|
| Cell Assay |
For cellular assays, AML cell lines (e.g., MOLM-13, MV4-11) or other cancer cell lines are cultured in appropriate media and treated with various concentrations of MB-3 (typically 0.1-100 μM) for 24-72 hours. Cell viability is assessed using MTT or CellTiter-Glo assays. Apoptosis is evaluated by flow cytometry using Annexin V/PI staining. Cell differentiation is assessed by measuring cell surface markers (e.g., CD11b, CD14) by flow cytometry. Histone acetylation is analyzed by Western blotting. Gene expression is analyzed by qPCR or RNA-seq.
|
| Animal Protocol |
In vivo, MB-3 is typically administered intraperitoneally or orally to mice bearing tumor xenografts. Doses typically range from 10-100 mg/kg administered daily or every other day. Tumor growth is monitored by measuring tumor volume. At the end of the study, tumors are excised and analyzed for histone acetylation, cell proliferation (Ki-67 staining), and apoptosis (TUNEL staining). Pharmacokinetic studies involve measurement of MB-3 levels in plasma and tissues by LC-MS/MS.
|
| ADME/Pharmacokinetics |
MB-3 has a specific molecular weight and formula, though detailed physicochemical properties are not provided in the search results. The compound is soluble in DMSO and should be stored at -20°C under appropriate conditions to maintain stability. Pharmacokinetic parameters such as bioavailability, half-life, and tissue distribution are not detailed in the provided search results.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for MB-3 is not available in the provided search results. As a HAT inhibitor, it may affect normal cellular processes that depend on histone acetylation, including gene expression, cell proliferation, and differentiation. The compound has been studied in animal models and appears to be well-tolerated at therapeutic doses. Comprehensive toxicological studies are required to establish its full safety profile.
|
| References |
|
| Additional Infomation |
(2S,3R)-4-methylene-5-oxo-2-propyl-3-oxacyclopentanecarboxylic acid is a γ-lactone.
MB-3 is a research compound that has been developed as a selective inhibitor of MOZ/KAT6A HAT activity. MOZ and KAT6A are histone acetyltransferases that are overexpressed or mutated in various cancers, including acute myeloid leukemia. By inhibiting these enzymes, MB-3 offers a potential therapeutic strategy for targeting epigenetic dysregulation in cancer. The compound is not approved for clinical use and is intended for research purposes only. It is available from chemical suppliers for research applications. |
| Molecular Formula |
C9H12O4
|
|---|---|
| Molecular Weight |
184.19
|
| Exact Mass |
184.073
|
| CAS # |
778649-18-6
|
| PubChem CID |
10081070
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
386.2±42.0 °C at 760 mmHg
|
| Flash Point |
158.5±21.4 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.495
|
| LogP |
0.99
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
13
|
| Complexity |
256
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CCC[C@H]1[C@@H](C(=C)C(=O)O1)C(=O)O
|
| InChi Key |
SRQUTZJZABSZRQ-NKWVEPMBSA-N
|
| InChi Code |
InChI=1S/C9H12O4/c1-3-4-6-7(8(10)11)5(2)9(12)13-6/h6-7H,2-4H2,1H3,(H,10,11)/t6-,7+/m0/s1
|
| Chemical Name |
(2S,3R)-4-methylidene-5-oxo-2-propyloxolane-3-carboxylic acid
|
| Synonyms |
MB3; MB 3; MB-3
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~542.92 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (11.29 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (11.29 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (11.29 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.4292 mL | 27.1459 mL | 54.2918 mL | |
| 5 mM | 1.0858 mL | 5.4292 mL | 10.8584 mL | |
| 10 mM | 0.5429 mL | 2.7146 mL | 5.4292 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
